Approval · Notice of Compliance 1763 · 1999
TEVETEN: Notice of Compliance 1763
Issued July 7, 1999
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 1763
- Date
- July 7, 1999
- Company
- Smithkline Beecham Pharma, Division Of Smithkline Beecham Inc.Mississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
- Therapeutic class
- Angiotensin ii receptor (at1) antagonist
Products in this notice
Medicinal ingredients
- EPROSARTAN MESYLATE 300 MG per TAB
- EPROSARTAN MESYLATE 400 MG per TAB